Stock TECH BIO-TECHNE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
64.06 USD +2.23% Intraday chart for Bio-Techne Corporation +3.12% -16.98%
Apr. 26 Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay CI
Apr. 23 Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,896 10,094 17,511 13,600 12,852 10,070 - -
Enterprise Value (EV) 1 8,235 10,179 17,621 13,609 12,997 10,256 10,059 9,708
P/E ratio 84.4 x 45.4 x 130 x 52.3 x 46.4 x 57.7 x 45.1 x 38.3 x
Yield 0.61% 0.48% 0.28% 0.37% - 0.5% 0.5% 0.52%
Capitalization / Revenue 11.1 x 13.7 x 18.8 x 12.3 x 11.3 x 8.78 x 8.09 x 7.3 x
EV / Revenue 11.5 x 13.8 x 18.9 x 12.3 x 11.4 x 8.95 x 8.08 x 7.04 x
EV / EBITDA 31.2 x 38 x 45.7 x 30.3 x 29.5 x 25.5 x 22 x 18.8 x
EV / FCF 52.7 x 66.4 x 57.2 x 48.5 x 60.1 x 39 x 30.3 x 27.8 x
FCF Yield 1.9% 1.51% 1.75% 2.06% 1.66% 2.57% 3.3% 3.6%
Price to Book 6.96 x 7.53 x 11.2 x 8.36 x 6.72 x 4.88 x 4.36 x 3.87 x
Nbr of stocks (in thousands) 151,491 152,892 155,567 156,934 157,437 157,192 - -
Reference price 2 52.12 66.02 112.6 86.66 81.63 64.06 64.06 64.06
Announcement Date 8/6/19 8/4/20 8/5/21 8/4/22 8/8/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 714 738.7 931 1,106 1,137 1,146 1,245 1,380
EBITDA 1 264.3 268.1 385.7 449.3 441 401.5 456.7 516.9
EBIT 1 244.7 246.3 362.2 421.3 410.2 367.1 422 475.1
Operating Margin 34.27% 33.34% 38.9% 38.11% 36.09% 32.02% 33.9% 34.44%
Earnings before Tax (EBT) 1 112 276.5 148.2 301.4 338.7 201.8 272.8 332.2
Net income 1 96.07 229.3 140.4 272.1 285.3 178.8 228.5 267.6
Net margin 13.46% 31.04% 15.08% 24.61% 25.1% 15.6% 18.36% 19.39%
EPS 2 0.6175 1.455 0.8675 1.658 1.760 1.110 1.420 1.672
Free Cash Flow 1 156.2 153.2 307.9 280.4 216.1 263.2 331.9 349.1
FCF margin 21.88% 20.75% 33.07% 25.36% 19.02% 22.96% 26.66% 25.31%
FCF Conversion (EBITDA) 59.09% 57.15% 79.82% 62.4% 49.01% 65.55% 72.68% 67.54%
FCF Conversion (Net income) 162.59% 66.83% 219.26% 103.06% 75.77% 147.19% 145.23% 130.49%
Dividend per Share 2 0.3200 0.3200 0.3200 0.3200 - 0.3200 0.3200 0.3333
Announcement Date 8/6/19 8/4/20 8/5/21 8/4/22 8/8/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 257.7 269.3 290.4 288.2 269.7 271.6 294.1 301.3 276.9 272.6 292.8 304.6 291.5 297 320
EBITDA 1 103.7 109.5 121.8 114.3 100.5 104 116.4 120 95.58 93.23 103.4 112.7 103.4 106.3 119.5
EBIT 1 97.35 102.8 114.6 106.6 93.18 96.47 108.7 111.8 86.89 81.94 94.38 103.3 94.61 97.65 110.3
Operating Margin 37.77% 38.19% 39.45% 36.97% 34.55% 35.52% 36.96% 37.12% 31.38% 30.06% 32.24% 33.92% 32.45% 32.87% 34.48%
Earnings before Tax (EBT) 1 67.38 86.18 68.77 79.05 103.7 66.43 80.2 88.32 49.56 33.39 56 63.42 56.68 62.65 74.72
Net income 1 69.62 80.17 60.74 61.52 89.56 50 70.22 75.48 50.99 27.46 46.7 54.04 47.19 52.15 61.29
Net margin 27.01% 29.77% 20.92% 21.35% 33.21% 18.41% 23.87% 25.05% 18.41% 10.08% 15.95% 17.74% 16.19% 17.56% 19.15%
EPS 2 0.4225 0.4850 0.3700 0.3775 0.5525 0.3100 0.4300 0.4700 0.3100 0.1700 0.2880 0.3380 0.3000 0.3250 0.3850
Dividend per Share 2 0.0800 0.0800 0.0800 0.0800 0.0800 0.0800 0.0800 - 0.0800 - 0.0800 0.0800 0.0800 0.0800 0.0800
Announcement Date 11/2/21 2/1/22 5/4/22 8/4/22 11/1/22 2/2/23 5/3/23 8/8/23 10/31/23 2/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 339 85.9 110 8.88 146 187 - -
Net Cash position 1 - - - - - - 10.8 362
Leverage (Debt/EBITDA) 1.283 x 0.3202 x 0.2846 x 0.0198 x 0.3304 x 0.4652 x - -
Free Cash Flow 1 156 153 308 280 216 263 332 349
ROE (net income / shareholders' equity) 15.6% 14.1% 9.51% 16.6% 17.5% 14.3% 14.7% 15%
ROA (Net income/ Total Assets) 10.1% 9.17% 6.55% 11.9% 13% 11.3% 12% 12.7%
Assets 1 952.1 2,501 2,145 2,279 2,189 1,588 1,910 2,105
Book Value Per Share 2 7.490 8.760 10.00 10.40 12.10 13.10 14.70 16.50
Cash Flow per Share 2 1.170 1.300 2.170 1.980 1.570 2.000 2.230 2.510
Capex 1 25.4 51.7 44.3 44.9 38.2 53 56 57.9
Capex / Sales 3.56% 7% 4.76% 4.06% 3.36% 4.63% 4.5% 4.2%
Announcement Date 8/6/19 8/4/20 8/5/21 8/4/22 8/8/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bio-Techne Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
64.06 USD
Average target price
80.43 USD
Spread / Average Target
+25.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-16.98% 10.07B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TECH Stock
  4. Financials Bio-Techne Corporation